Last updated on September 2018

Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+ HER2-negative aBC With PIK3CA Mutations Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant


Brief description of study

Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+, HER2-negative aBC, with PIK3CA mutations, whose disease has progressed on or after CDK 4/6 treatment with an aromatase inhibitor (AI) or fulvestrant

Clinical Study Identifier: NCT03056755

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Tel Aviv, Israel
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Ramat Gan, Israel
2.79miles
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Petach Tikva, Israel
6.21miles
  Connect »